Breaking News Instant updates and real-time market news.

PFE

Pfizer

$35.79

-0.16 (-0.45%)

, BMY

Bristol-Myers

$60.18

-1.03 (-1.68%)

06:57
04/12/18
04/12
06:57
04/12/18
06:57

Pfizer has no interest in acquiring Bristol-Myers right now, says Citi

Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.

PFE

Pfizer

$35.79

-0.16 (-0.45%)

BMY

Bristol-Myers

$60.18

-1.03 (-1.68%)

MRK

Merck

$56.20

-0.29 (-0.51%)

LLY

Eli Lilly

$78.73

-0.49 (-0.62%)

  • 14

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 01

    May

  • 07

    May

  • 08

    May

  • 05

    Jun

  • 07

    Jun

  • 10

    Jul

  • 23

    Oct

PFE Pfizer
$35.79

-0.16 (-0.45%)

04/05/18
04/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Hold from Buy at Stifel with analyst Kevin Cassidy citing the peaking server central processing unit cycle and valuation for the downgrade. 2. Johnson Controls (JCI) downgraded to Underperform from Sector Perform at RBC Capital with analyst Deane Dray citing the company's exposure to additional cash flow pressures in fiscal 2018, reduction in fiscal 2020 targets, and a market rotation toward "more defensive names." 3. Ryder (R) downgraded to Underweight from Neutral at JPMorgan with analyst Brian Ossenbeck saying he is making a "longer term call on 2019 expectations," which he believes are too high and embed "significant gains on residual values and used truck sales." 4. Ollie's Bargain Outlet (OLLI) downgraded to Neutral from Buy at BofA/Merrill with analyst Elizabeth Suzuki saying valuation is getting "richer," quarterly comps have been decelerating since 2015, and are now expected to be 1%-2% in 2018. 5. Biogen (BIIB), Pfizer (PFE), Biohaven (BHVN), and Myovant Sciences (MYOV) were downgraded to Equal Weight from Overweight at Barclays. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/18
LEHM
04/05/18
NO CHANGE
LEHM
Barclays upgrades Merck, downgrades Biogen and Pfizer in sector reassessment
Barclays analyst Geoff Meacham made some rating changes while reassessing the Biopharmaceutical sector. Biopharma sentiment has been negative since the start of 2018, despite a modest pick-up in deals and diminished rhetoric on drug pricing, Meacham tells investors in a research note titled "U.S. Biopharmaceuticals: Where to from here?" The analyst believes "more transformative" acquisitions, "clean" Phase 3 wins, and even a relatively strong Q1 earnings season could help "re-rate the sector" and get investors more engaged in the group. Ahead of the Q1 earnings season, Meacham upgraded Merck (MRK) to Overweight from Equal Weight and downgraded to Equal Weight from Overweight shares of Biogen (BIIB), Pfizer (PFE), Biohaven Pharmaceutical (BHVN) and Myovant Sciences (MYOV). The analyst also lowered his price target for Equal Weight-rated AbbVie (ABBV) to $102 from $120, for Equal Weight-rated Amgen (AMGN) to $180 from $180, for Overweight-rated Prothena (PRTA) to $50 from $70 and for Overweight-rated Incyte (INCY) to $135 from $165.
04/05/18
LEHM
04/05/18
DOWNGRADE
Target $38
LEHM
Equal Weight
Pfizer downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoffrey Meacham downgraded Pfizer to Equal Weight and lowered his price target for the shares to $38 from $41. The analyst believes the stock at current levels largely capture the upside for key products like Prevnar, Ibrance, Xeljanz and Xtandi. He believes a transformative acquisition to accelerate Pfizer's growth is now less likely in the near term.
04/03/18
JMPS
04/03/18
NO CHANGE
Target $207
JMPS
Outperform
JMP Securities says Alnylam selloff an 'extreme overreaction' to competitor data
After speaking to Alnylam (ALNY) management about competitor Pfizer's (PFE) positive top-line trial results for tafamidis in patients with transthyretin cardiomyopathy, JMP Securities analyst Michael King said Alnylam believes patisiran has a superior competitive profile compared to tafamidis in patients with hATTR-FAP. He views the selloff in Alnylam shares as "an extreme overreaction" to the presence of a competitor, reminding investors of recent International Symposium on Amyloidosis data that he said suggest that ALN-TTRsc02 will be well positioned with respect to tafamidis. King reiterates his Outperform rating and $207 price target on Alnylam.
BMY Bristol-Myers
$60.18

-1.03 (-1.68%)

03/20/18
JPMS
03/20/18
NO CHANGE
Target $75
JPMS
Overweight
Bristol-Myers price target raised to $75 from $70 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Bristol-Myers Squibb to $75 saying the company's opportunity in non-lung tumor types is broad and underappreciated. The analyst sees a number of $1B-plus indications for Opdivo beyond non-small-cell lung carcinoma, including kidney, liver, gastric, small cell lung and melanoma. These indications should represent the majority of Opdivo sales over time, Schott tells investors in a research note. The analyst keeps an Overweight rating on Bristol-Myers.
04/06/18
MZHO
04/06/18
NO CHANGE
Target $103
MZHO
Buy
Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover
Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.
04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.
03/12/18
LEER
03/12/18
UPGRADE
Target $66
LEER
Outperform
Leerink upgrades Merck to Outperform ahead of KN-189 presentation
Leerink analyst Seamus Fernandez upgraded Merck (MRK) to Outperform from Market Perform with an unchanged price target of $66. The shares closed Friday up 38c to $55.14. Keytruda will continue to dominate the first-line non-small cell lung cancer market, Fernandez tells investors in a research note. Following his firm's lung cancer survey, the analyst believes Merck will deliver upside to consensus Keytruda estimates along with positive earnings leverage in the second half of 2018 and 2019. He thinks KN-189 likely will show a clinically meaningful overall survival benefit for the Keytruda plus chemo combo in all patients, including a strong benefit in patients with moderate or low PD-L1 biomarker levels. Fernandez does not believe Bristol-Myers' (BMY) Opdivo and Yervoy combo will supplant Keytruda as the market leader. The analyst thinks now is the time to own shares of Merck.
MRK Merck
$56.20

-0.29 (-0.51%)

04/09/18
JEFF
04/09/18
DOWNGRADE
Target $4
JEFF
Hold
NewLink Genetics downgraded to Hold with $4 target at Jefferies
Jefferies analyst Biren Amin late Friday downgraded NewLink Genetics (NLNK) to Hold from Buy and cut his price target for the shares to $4 from $17. The stock closed Friday down 43%, or $3.12, to $4.20. The analyst does not see a scenario in which the company's IDO inhibitor can avoid the same fate as Incyte and Merck's epacadostat plus Keytruda failed study.
04/09/18
OPCO
04/09/18
NO CHANGE
Target $65
OPCO
Perform
Incyte price target lowered to $65 from $110 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte (INCY) to $65 from $110 following the update on the termination of ECHO-301 after epacadostat failed to show a PFS or OS benefit when combined with Merck's (MRK) Keytruda versus Keytruda alone. While the company plans to conduct subgroup analyses of ECHO-301 looking at various biomarkers such as PD-L1 expression and tumor mutational burden which may provide additional insights, the analyst sees no reason at this time to continue development of epacadostat as he considers it highly unlikely to demonstrate efficacy in other tumor types and/or combinations. Olson reiterates a Perform rating on Incyte's shares.
LLY Eli Lilly
$78.73

-0.49 (-0.62%)

02/26/18
JPMS
02/26/18
NO CHANGE
Target $105
JPMS
Overweight
Concerns over Eli Lilly diabetes franchise overdone, says JPMorgan
JPMorgan analyst Chris Schott believes longer-term growth concerns surrounding Trulicity and Eli Lilly's (LLY) broader diabetes franchise are overdone following Novo Nordisk's (NVO) oral semaglutide results as well as the launch of Ozempic. The analyst sees a buying opportunity in shares of Eli Lilly following the recent pullback. Lilly is a "highly diversified growth story" and competition to Trulicity is manageable, Schott tells investors in a research note. He keeps an Overweight rating on the shares with a $105 price target.
03/27/18
03/27/18
UPGRADE
Target $8

Buy
Aratana Therapeutics upgraded on Entyce traction, M&A potential at Stifel
As previously reported, Stifel analyst Jonathan Block upgraded Aratana Therapeutics (PETX) to Buy from Hold. The early traction for Entyce, which was launched October 2017, has increased his conviction that the drug will act as the main revenue driver for Aratana in coming years, Block tells investors. Additionally, he argues that Aratana's portfolio may be appealing to a big animal health company, with Lilly's (LLY) Elanco viewed by Block as the most obvious candidate. The analyst raised his price target on Aratana shares to $8 from $6.
04/05/18
RHCO
04/05/18
NO CHANGE
Target $101
RHCO
Buy
Eli Lilly supported by positive oncology and diabetes findings, says SunTrust
SunTrust analyst John Boris keeps his Buy rating and $101 price target on Eli Lilly (LLY), citing the latest developments in Oncology and Diabetes. In Oncology, Boris points to the positive Overall Survival and Progression Free Survival data for Cyramza in second-line hepatocellular carcinoma, though he sees the commercial opportunity in Hepatocellular Carcinoma as limited. In Diabetes, the analyst points to the latest data showing Trulicity gaining market share on Novo Nordisk's (NVO) Victoza in the GLP-1 market.
02/01/18
LEER
02/01/18
NO CHANGE
Target $98
LEER
Market Perform
Eli Lilly selloff an overreaction, says Leerink
Following Q4 results, updated 2018 tax and EPS guidance, Leerink analyst Seamus Fernandez tells investors that the pressure in Eli Lilly's shares was "surprising." The analyst views the move as an "overreaction" by investors, but acknowledges that 2018 poses some legitimate risks for diabetes and animal health franchises which we highlighted in an earlier note. It its "hard to get excited" given competitive headwinds, but valuation downside is limited, he contends. Fernandez reiterates a Market Perform rating on the stock, while raised his price target on the shares to $98 from $95 due to the benefit of tax.

TODAY'S FREE FLY STORIES

FNWB

First Northwest Bancorp

$16.11

0.36 (2.29%)

17:48
07/20/18
07/20
17:48
07/20/18
17:48
Hot Stocks
First Northwest Bancorp names Terry Anderson chief credit officer »

First Northwest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.75

-0.05 (-0.32%)

17:42
07/20/18
07/20
17:42
07/20/18
17:42
Hot Stocks
Freeport McMoRan CAO Michael Arnold to retire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

, XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

17:39
07/20/18
07/20
17:39
07/20/18
17:39
General news
Week ending ETF Scorecard: Financials lead, Energy slumps »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

IYR

DJ US Real Estate Index Fund

$80.23

-0.68 (-0.84%)

XLP

Consumer Staples Sector SPDR

$52.84

0.3 (0.57%)

XLY

Consumer Discretionary Sector SPDR

$112.15

-0.47 (-0.42%)

XLB

S&P Select Materials SPDR

$58.31

-0.21 (-0.36%)

XLF

Financial Select Sector

$27.57

0.065 (0.24%)

XLV

Health Care Select Sector SPDR

$86.74

-0.17 (-0.20%)

XLK

Technology Select Sector SPDR

$72.55

0.01 (0.01%)

XLI

Industrial Select Sector SPDR

$74.44

-0.09 (-0.12%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

SLV

iShares Silver Trust

$14.59

0.18 (1.25%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

UNG

United States Natural Gas Fund

$22.38

-0.06 (-0.27%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.62

0.03 (0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.27

-0.335 (-0.29%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.78

-1.46 (-1.19%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.21

-0.35 (-0.34%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

-0.005 (-0.01%)

IWD

iShares Russell 1000 Value

$123.07

-0.2897 (-0.23%)

IWF

iShares Russell 1000 Growth

$149.41

-0.04 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$25.10

-0.095 (-0.38%)

, FUJIY

Fujifilm

$0.00

(0.00%)

17:25
07/20/18
07/20
17:25
07/20/18
17:25
Hot Stocks
Xerox, Centerview settle matters related to proposed Fuji tie-up »

On July 20, 2018, Xerox…

XRX

Xerox

$25.10

-0.095 (-0.38%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

STON

StoneMor Partners

$3.61

-0.015 (-0.41%)

17:15
07/20/18
07/20
17:15
07/20/18
17:15
Hot Stocks
Breaking Hot Stocks news story on StoneMor Partners »

Oaktree Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

$8.70

0.07 (0.81%)

17:11
07/20/18
07/20
17:11
07/20/18
17:11
Downgrade
Telefonica rating change at Goldman Sachs »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

, USO

United States Oil Fund

$14.15

0.025 (0.18%)

17:04
07/20/18
07/20
17:04
07/20/18
17:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 5.5K…

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

FXE

Euro Currency Trust

$112.46

0.83 (0.74%)

FXC

CurrencyShares Canadian Dollar Trust

$75.17

0.81 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.15

(0.00%)

17:02
07/20/18
07/20
17:02
07/20/18
17:02
Syndicate
Breaking Syndicate news story on Citizens Community Bancorp »

Citizens Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKD

Parker Drilling

$0.30

-0.0044 (-1.46%)

17:01
07/20/18
07/20
17:01
07/20/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Parker Drilling »

Whitebox Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

RSLS

ReShape Lifesciences

$1.47

-0.02 (-1.34%)

17:00
07/20/18
07/20
17:00
07/20/18
17:00
Hot Stocks
Breaking Hot Stocks news story on ReShape Lifesciences  »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOX

Box

$26.13

-0.26 (-0.99%)

16:57
07/20/18
07/20
16:57
07/20/18
16:57
Initiation
Box initiated at First Analysis »

Box initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$7.95

-0.15 (-1.85%)

16:53
07/20/18
07/20
16:53
07/20/18
16:53
Syndicate
Breaking Syndicate news story on Aldeyra »

Aldeyra files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLRE

Greenlight Capital Re

$14.00

-0.15 (-1.06%)

16:46
07/20/18
07/20
16:46
07/20/18
16:46
Hot Stocks
Greenlight Capital Re announces departure of COO »

Greenlight Capital Ry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVI

Retail Value

$34.56

0.2 (0.58%)

16:38
07/20/18
07/20
16:38
07/20/18
16:38
Hot Stocks
Breaking Hot Stocks news story on Retail Value »

Luxor Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

, ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

16:35
07/20/18
07/20
16:35
07/20/18
16:35
Hot Stocks
Lincoln Electric expands board to 11 directors, appoints Patrick Goris to board »

Lincoln Electric (LECO)…

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

KMX

CarMax

$77.15

-0.57 (-0.73%)

16:33
07/20/18
07/20
16:33
07/20/18
16:33
Hot Stocks
CarMax chairman sells 37,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$100.65

-0.74 (-0.73%)

16:31
07/20/18
07/20
16:31
07/20/18
16:31
Hot Stocks
Lowe's names Joseph McFarland as EVP of stores »

Lowe's Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
07/20/18
07/20
16:30
07/20/18
16:30
Options
Preliminary option volume of 20.2M today »

Preliminary option volume…

PFE

Pfizer

$37.33

-0.03 (-0.08%)

16:26
07/20/18
07/20
16:26
07/20/18
16:26
Hot Stocks
FDA approves Pfizer's Biosimilar NIVESTYM for all indications »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

JCP

J.C. Penney

$2.50

-0.065 (-2.53%)

16:23
07/20/18
07/20
16:23
07/20/18
16:23
Hot Stocks
J.C. Penney chief customer officer McFarland to leave company »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/20/18
07/20
16:20
07/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for July 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$3.15

-0.1 (-3.08%)

16:18
07/20/18
07/20
16:18
07/20/18
16:18
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/20/18
07/20
16:17
07/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/20/18
07/20
16:16
07/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

16:15
07/20/18
07/20
16:15
07/20/18
16:15
Periodicals
Disney fires 'Guardians' director after controversial tweets, THR says »

Disney has fired James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.